TY - JOUR AU - Urban, D. AU - Poss, J. AU - Bohm, M. AU - Laufs, U. PY - 2013 DA - 2013// TI - Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis JO - J Am Coll Cardiol VL - 62 UR - https://doi.org/10.1016/j.jacc.2013.07.056 DO - 10.1016/j.jacc.2013.07.056 ID - Urban2013 ER - TY - JOUR AU - Seidah, N. G. AU - Awan, Z. AU - Chretien, M. AU - Mbikay, M. PY - 2014 DA - 2014// TI - PCSK9: a key modulator of cardiovascular health JO - Circ Res VL - 114 UR - https://doi.org/10.1161/CIRCRESAHA.114.301621 DO - 10.1161/CIRCRESAHA.114.301621 ID - Seidah2014 ER - TY - JOUR AU - Lakoski, S. G. AU - Lagace, T. A. AU - Cohen, J. C. AU - Horton, J. D. AU - Hobbs, H. H. PY - 2009 DA - 2009// TI - Genetic and metabolic determinants of plasma PCSK9 levels JO - J Clin Endocrinol Metab VL - 94 UR - https://doi.org/10.1210/jc.2009-0141 DO - 10.1210/jc.2009-0141 ID - Lakoski2009 ER - TY - JOUR AU - Brouwers, M. C. G. J. AU - Troutt, J. S. AU - Greevenbroek, M. M. J. AU - Ferreira, I. AU - Feskens, E. J. AU - Kallen, C. J. H. PY - 2011 DA - 2011// TI - Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study JO - Atherosclerosis VL - 217 UR - https://doi.org/10.1016/j.atherosclerosis.2011.03.023 DO - 10.1016/j.atherosclerosis.2011.03.023 ID - Brouwers2011 ER - TY - JOUR AU - Persson, L. AU - Galman, C. AU - Angelin, B. AU - Rudling, M. PY - 2009 DA - 2009// TI - Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors JO - Endocrinology VL - 150 UR - https://doi.org/10.1210/en.2008-1281 DO - 10.1210/en.2008-1281 ID - Persson2009 ER - TY - JOUR AU - Awan, Z. AU - Dubuc, G. AU - Faraj, M. AU - Dufour, R. AU - Seidah, N. G. AU - Davignon, J. PY - 2014 DA - 2014// TI - The effect of insulin on circulating PCSK9 in postmenopausal obese women JO - Clin Biochem VL - 47 UR - https://doi.org/10.1016/j.clinbiochem.2014.03.022 DO - 10.1016/j.clinbiochem.2014.03.022 ID - Awan2014 ER - TY - JOUR AU - Mbikay, M. AU - Sirois, F. AU - Mayne, J. AU - Wang, G. S. AU - Chen, A. AU - Dewpura, T. PY - 2010 DA - 2010// TI - PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities JO - FEBS Lett VL - 584 UR - https://doi.org/10.1016/j.febslet.2009.12.018 DO - 10.1016/j.febslet.2009.12.018 ID - Mbikay2010 ER - TY - JOUR AU - Langhi, C. AU - May, C. AU - Gmyr, V. AU - Vandewalle, B. AU - Kerr-Conte, J. AU - Krempf, M. PY - 2009 DA - 2009// TI - PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion JO - Biochem Biophys Res Commun VL - 390 UR - https://doi.org/10.1016/j.bbrc.2009.10.138 DO - 10.1016/j.bbrc.2009.10.138 ID - Langhi2009 ER - TY - JOUR AU - Yang, S. H. AU - Li, S. AU - Zhang, Y. AU - Xu, R. X. AU - Guo, Y. L. AU - Zhu, C. G. PY - 2016 DA - 2016// TI - Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes JO - Diab Metab Res Rev VL - 32 UR - https://doi.org/10.1002/dmrr.2712 DO - 10.1002/dmrr.2712 ID - Yang2016 ER - TY - JOUR AU - Baass, A. AU - Dubuc, G. AU - Tremblay, M. AU - Delvin, E. E. AU - O’Loughlin, J. AU - Levy, E. PY - 2009 DA - 2009// TI - Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents JO - Clin Chem VL - 55 UR - https://doi.org/10.1373/clinchem.2009.126987 DO - 10.1373/clinchem.2009.126987 ID - Baass2009 ER - TY - JOUR AU - Cui, Q. AU - Ju, X. AU - Yang, T. AU - Zhang, M. AU - Tang, W. AU - Chen, Q. PY - 2010 DA - 2010// TI - Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population JO - Atherosclerosis VL - 213 UR - https://doi.org/10.1016/j.atherosclerosis.2010.09.027 DO - 10.1016/j.atherosclerosis.2010.09.027 ID - Cui2010 ER - TY - JOUR AU - Dong, B. AU - Singh, A. B. AU - Azhar, S. AU - Seidah, N. G. AU - Liu, J. PY - 2015 DA - 2015// TI - High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels JO - Atherosclerosis VL - 239 UR - https://doi.org/10.1016/j.atherosclerosis.2015.01.013 DO - 10.1016/j.atherosclerosis.2015.01.013 ID - Dong2015 ER - TY - JOUR AU - Awan, Z. AU - Delvin, E. E. AU - Levy, E. AU - Genest, J. AU - Davignon, J. AU - Seidah, N. G. PY - 2013 DA - 2013// TI - Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype JO - Can J Cardiol VL - 29 UR - https://doi.org/10.1016/j.cjca.2013.03.004 DO - 10.1016/j.cjca.2013.03.004 ID - Awan2013 ER - TY - JOUR AU - Colhoun, H. M. AU - Ginsberg, H. N. AU - Robinson, J. G. AU - Leiter, L. A. AU - Muller-Wieland, D. AU - Henry, R. R. PY - 2016 DA - 2016// TI - No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies JO - Eur Heart J VL - 37 UR - https://doi.org/10.1093/eurheartj/ehw292 DO - 10.1093/eurheartj/ehw292 ID - Colhoun2016 ER - TY - JOUR AU - Sabatine, M. S. AU - Leiter, L. A. AU - Wiviott, S. D. AU - Giugliano, R. P. AU - Deedwania, P. AU - Ferrari, G. M. PY - 2017 DA - 2017// TI - Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial JO - Lancet Diab Endocrinol VL - 5 UR - https://doi.org/10.1016/S2213-8587(17)30313-3 DO - 10.1016/S2213-8587(17)30313-3 ID - Sabatine2017 ER - TY - JOUR AU - Lotta, L. A. AU - Sharp, S. J. AU - Burgess, S. AU - Perry, J. R. B. AU - Stewart, I. D. AU - Willems, S. M. PY - 2016 DA - 2016// TI - Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis JO - JAMA VL - 316 UR - https://doi.org/10.1001/jama.2016.14568 DO - 10.1001/jama.2016.14568 ID - Lotta2016 ER - TY - JOUR AU - Ference, B. A. AU - Robinson, J. G. AU - Brook, R. D. AU - Catapano, A. L. AU - Chapman, M. J. AU - Neff, D. R. PY - 2016 DA - 2016// TI - Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1604304 DO - 10.1056/NEJMoa1604304 ID - Ference2016 ER - TY - JOUR AU - Zinman, B. AU - Gerich, J. AU - Buse, J. B. AU - Lewin, A. AU - Schwartz, S. AU - Raskin, P. PY - 2009 DA - 2009// TI - Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) JO - Diabetes Care VL - 32 UR - https://doi.org/10.2337/dc08-2124 DO - 10.2337/dc08-2124 ID - Zinman2009 ER - TY - JOUR AU - Marre, M. AU - Shaw, J. AU - Brandle, M. AU - Bebakar, W. M. AU - Kamaruddin, N. A. AU - Strand, J. PY - 2009 DA - 2009// TI - Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) JO - Diabet Med VL - 26 UR - https://doi.org/10.1111/j.1464-5491.2009.02666.x DO - 10.1111/j.1464-5491.2009.02666.x ID - Marre2009 ER - TY - JOUR AU - Yang, W. AU - Chen, L. AU - Ji, Q. AU - Liu, X. AU - Ma, J. AU - Tandon, N. PY - 2011 DA - 2011// TI - Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial JO - Diab Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2010.01323.x DO - 10.1111/j.1463-1326.2010.01323.x ID - Yang2011 ER - TY - JOUR AU - Davies, M. J. AU - Bergenstal, R. AU - Bode, B. AU - Kushner, R. F. AU - Lewin, A. AU - Skjoth, T. V. PY - 2015 DA - 2015// TI - Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial JO - JAMA VL - 314 UR - https://doi.org/10.1001/jama.2015.9676 DO - 10.1001/jama.2015.9676 ID - Davies2015 ER - TY - JOUR AU - Astrup, A. AU - Rossner, S. AU - Gaal, L. AU - Rissanen, A. AU - Niskanen, L. AU - Al Hakim, M. PY - 2009 DA - 2009// TI - Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study JO - Lancet VL - 374 UR - https://doi.org/10.1016/S0140-6736(09)61375-1 DO - 10.1016/S0140-6736(09)61375-1 ID - Astrup2009 ER - TY - JOUR AU - Marso, S. P. AU - Daniels, G. H. AU - Brown-Frandsen, K. AU - Kristensen, P. AU - Mann, J. F. AU - Nauck, M. A. PY - 2016 DA - 2016// TI - Liraglutide and cardiovascular outcomes in type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1603827 DO - 10.1056/NEJMoa1603827 ID - Marso2016 ER - TY - JOUR AU - Chang, Y. AU - Yang, S. T. AU - Liu, J. H. AU - Dong, E. AU - Wang, Y. AU - Cao, A. PY - 2011 DA - 2011// TI - In vitro toxicity evaluation of graphene oxide on A549 cells JO - Toxicol Lett VL - 200 UR - https://doi.org/10.1016/j.toxlet.2010.11.016 DO - 10.1016/j.toxlet.2010.11.016 ID - Chang2011 ER - TY - JOUR AU - Deng, X. AU - Luan, Q. AU - Chen, W. AU - Wang, Y. AU - Wu, M. AU - Zhang, H. PY - 2009 DA - 2009// TI - Nanosized zinc oxide particles induce neural stem cell apoptosis JO - Nanotechnology VL - 20 UR - https://doi.org/10.1088/0957-4484/20/11/115101 DO - 10.1088/0957-4484/20/11/115101 ID - Deng2009 ER - TY - JOUR AU - Shimoda, M. AU - Kanda, Y. AU - Hamamoto, S. AU - Tawaramoto, K. AU - Hashiramoto, M. AU - Matsuki, M. PY - 2011 DA - 2011// TI - The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes JO - Diabetologia VL - 54 UR - https://doi.org/10.1007/s00125-011-2069-9 DO - 10.1007/s00125-011-2069-9 ID - Shimoda2011 ER - TY - JOUR AU - Kimura, T. AU - Kaneto, H. AU - Shimoda, M. AU - Hirukawa, H. AU - Okauchi, S. AU - Kohara, K. PY - 2015 DA - 2015// TI - Protective effects of pioglitazone and/or liraglutide on pancreatic beta-cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes JO - Mol Cell Endocrinol VL - 400 UR - https://doi.org/10.1016/j.mce.2014.11.018 DO - 10.1016/j.mce.2014.11.018 ID - Kimura2015 ER - TY - JOUR AU - Chong, B. F. AU - Murphy, J. E. AU - Kupper, T. S. AU - Fuhlbrigge, R. C. PY - 2004 DA - 2004// TI - E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system JO - J Immunol VL - 172 UR - https://doi.org/10.4049/jimmunol.172.3.1575 DO - 10.4049/jimmunol.172.3.1575 ID - Chong2004 ER - TY - JOUR AU - Lerat, H. AU - Honda, M. AU - Beard, M. R. AU - Loesch, K. AU - Sun, J. AU - Yang, Y. PY - 2002 DA - 2002// TI - Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus JO - Gastroenterology VL - 122 UR - https://doi.org/10.1053/gast.2002.31001 DO - 10.1053/gast.2002.31001 ID - Lerat2002 ER - TY - JOUR AU - Norton, A. J. AU - Jordan, S. AU - Yeomans, P. PY - 1994 DA - 1994// TI - Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues JO - J Pathol VL - 173 UR - https://doi.org/10.1002/path.1711730413 DO - 10.1002/path.1711730413 ID - Norton1994 ER - TY - JOUR AU - Drucker, D. J. AU - Buse, J. B. AU - Taylor, K. AU - Kendall, D. M. AU - Trautmann, M. AU - Zhuang, D. PY - 2008 DA - 2008// TI - Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study JO - Lancet VL - 372 UR - https://doi.org/10.1016/S0140-6736(08)61206-4 DO - 10.1016/S0140-6736(08)61206-4 ID - Drucker2008 ER - TY - JOUR AU - Trujillo, J. M. AU - Nuffer, W. PY - 2014 DA - 2014// TI - GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents JO - Pharmacotherapy VL - 34 UR - https://doi.org/10.1002/phar.1507 DO - 10.1002/phar.1507 ID - Trujillo2014 ER - TY - JOUR AU - Pi-Sunyer, X. AU - Astrup, A. AU - Fujioka, K. AU - Greenway, F. AU - Halpern, A. AU - Krempf, M. PY - 2015 DA - 2015// TI - A randomized, controlled trial of 3.0 mg of liraglutide in weight management JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1411892 DO - 10.1056/NEJMoa1411892 ID - Pi-Sunyer2015 ER - TY - JOUR AU - Fujishima, Y. AU - Maeda, N. AU - Inoue, K. AU - Kashine, S. AU - Nishizawa, H. AU - Hirata, A. PY - 2012 DA - 2012// TI - Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes JO - Cardiovasc Diabetol VL - 11 UR - https://doi.org/10.1186/1475-2840-11-107 DO - 10.1186/1475-2840-11-107 ID - Fujishima2012 ER - TY - JOUR AU - Krause, G. C. AU - Lima, K. G. AU - Dias, H. B. AU - Silva, E. F. G. AU - Haute, G. V. AU - Basso, B. S. PY - 2017 DA - 2017// TI - Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells JO - Eur J Pharmacol VL - 809 UR - https://doi.org/10.1016/j.ejphar.2017.05.015 DO - 10.1016/j.ejphar.2017.05.015 ID - Krause2017 ER - TY - JOUR AU - Panjwani, N. AU - Mulvihill, E. E. AU - Longuet, C. AU - Yusta, B. AU - Campbell, J. E. AU - Brown, T. J. PY - 2013 DA - 2013// TI - GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(−/−) mice JO - Endocrinology VL - 154 UR - https://doi.org/10.1210/en.2012-1937 DO - 10.1210/en.2012-1937 ID - Panjwani2013 ER - TY - JOUR AU - Ruttimann, E. B. AU - Arnold, M. AU - Hillebrand, J. J. AU - Geary, N. AU - Langhans, W. PY - 2009 DA - 2009// TI - Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms JO - Endocrinology VL - 150 UR - https://doi.org/10.1210/en.2008-1221 DO - 10.1210/en.2008-1221 ID - Ruttimann2009 ER - TY - JOUR AU - Tang-Christensen, M. AU - Vrang, N. AU - Larsen, P. J. PY - 1998 DA - 1998// TI - Glucagon-like peptide 1 (7-36) amide’s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment JO - Diabetes VL - 47 UR - https://doi.org/10.2337/diabetes.47.4.530 DO - 10.2337/diabetes.47.4.530 ID - Tang-Christensen1998 ER - TY - JOUR AU - Xiao, C. AU - Dash, S. AU - Morgantini, C. AU - Adeli, K. AU - Lewis, G. F. PY - 2015 DA - 2015// TI - Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism JO - Diabetes VL - 64 UR - https://doi.org/10.2337/db14-1706 DO - 10.2337/db14-1706 ID - Xiao2015 ER - TY - JOUR AU - Farr, S. AU - Baker, C. AU - Naples, M. AU - Taher, J. AU - Iqbal, J. AU - Hussain, M. PY - 2015 DA - 2015// TI - Central nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a brain–gut axis JO - Arterioscler Thromb Vasc Biol VL - 35 UR - https://doi.org/10.1161/ATVBAHA.114.304873 DO - 10.1161/ATVBAHA.114.304873 ID - Farr2015 ER - TY - JOUR AU - Taher, J. AU - Baker, C. L. AU - Cuizon, C. AU - Masoudpour, H. AU - Zhang, R. AU - Farr, S. PY - 2014 DA - 2014// TI - GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance JO - Mol Metab VL - 3 UR - https://doi.org/10.1016/j.molmet.2014.09.005 DO - 10.1016/j.molmet.2014.09.005 ID - Taher2014 ER - TY - JOUR AU - Parlevliet, E. T. AU - Wang, Y. AU - Geerling, J. J. AU - Schroder-Van der Elst, J. P. AU - Picha, K. AU - O’Neil, K. PY - 2012 DA - 2012// TI - GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice JO - PLoS ONE VL - 7 UR - https://doi.org/10.1371/journal.pone.0049152 DO - 10.1371/journal.pone.0049152 ID - Parlevliet2012 ER - TY - JOUR AU - Kooijman, S. AU - Wang, Y. AU - Parlevliet, E. T. AU - Boon, M. R. AU - Edelschaap, D. AU - Snaterse, G. PY - 2015 DA - 2015// TI - Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice JO - Diabetologia VL - 58 UR - https://doi.org/10.1007/s00125-015-3727-0 DO - 10.1007/s00125-015-3727-0 ID - Kooijman2015 ER - TY - JOUR AU - Girona, J. AU - Ibarretxe, D. AU - Plana, N. AU - Guaita-Esteruelas, S. AU - Amigo, N. AU - Heras, M. PY - 2016 DA - 2016// TI - Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases JO - Cardiovasc Diabetol VL - 15 UR - https://doi.org/10.1186/s12933-016-0428-z DO - 10.1186/s12933-016-0428-z ID - Girona2016 ER - TY - JOUR AU - Armstrong, M. J. AU - Gaunt, P. AU - Aithal, G. P. AU - Barton, D. AU - Hull, D. AU - Parker, R. PY - 2016 DA - 2016// TI - Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)00803-X DO - 10.1016/S0140-6736(15)00803-X ID - Armstrong2016 ER - TY - JOUR AU - Petit, J. M. AU - Cercueil, J. P. AU - Loffroy, R. AU - Denimal, D. AU - Bouillet, B. AU - Fourmont, C. PY - 2017 DA - 2017// TI - Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study JO - J Clin Endocrinol Metab VL - 102 ID - Petit2017 ER - TY - JOUR AU - Baumeier, C. AU - Schluter, L. AU - Saussenthaler, S. AU - Laeger, T. AU - Rodiger, M. AU - Alaze, S. A. PY - 2017 DA - 2017// TI - Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease JO - Mol Metab VL - 6 UR - https://doi.org/10.1016/j.molmet.2017.07.016 DO - 10.1016/j.molmet.2017.07.016 ID - Baumeier2017 ER - TY - JOUR AU - Ao, N. AU - Yang, J. AU - Wang, X. AU - Du, J. PY - 2016 DA - 2016// TI - Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway JO - Hepatol Res VL - 46 UR - https://doi.org/10.1111/hepr.12551 DO - 10.1111/hepr.12551 ID - Ao2016 ER - TY - JOUR AU - Smits, M. M. AU - Tonneijck, L. AU - Muskiet, M. H. AU - Kramer, M. H. AU - Pouwels, P. J. AU - Pieters-van den Bos, I. C. PY - 2016 DA - 2016// TI - Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial JO - Diabetologia VL - 59 UR - https://doi.org/10.1007/s00125-016-4100-7 DO - 10.1007/s00125-016-4100-7 ID - Smits2016 ER - TY - JOUR AU - Tang, A. AU - Rabasa-Lhoret, R. AU - Castel, H. AU - Wartelle-Bladou, C. AU - Gilbert, G. AU - Massicotte-Tisluck, K. PY - 2015 DA - 2015// TI - Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial JO - Diabetes Care VL - 38 UR - https://doi.org/10.2337/dc14-2548 DO - 10.2337/dc14-2548 ID - Tang2015 ER - TY - JOUR AU - Du, Y. AU - Li, S. AU - Cui, C. J. AU - Zhang, Y. AU - Yang, S. H. AU - Li, J. J. PY - 2016 DA - 2016// TI - Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity JO - J Transl Med VL - 14 UR - https://doi.org/10.1186/s12967-016-1032-4 DO - 10.1186/s12967-016-1032-4 ID - Du2016 ER - TY - JOUR AU - Cui, C. J. AU - Li, S. AU - Zhu, C. G. AU - Sun, J. AU - Du, Y. AU - Zhang, Y. PY - 2016 DA - 2016// TI - Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1alpha pathway in HepG2 cells JO - J Cell Mol Med VL - 20 UR - https://doi.org/10.1111/jcmm.12931 DO - 10.1111/jcmm.12931 ID - Cui2016 ER - TY - JOUR AU - Miao, J. AU - Manthena, P. V. AU - Haas, M. E. AU - Ling, A. V. AU - Shin, D. J. AU - Graham, M. J. PY - 2015 DA - 2015// TI - Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9 JO - Arterioscler Thromb Vasc Biol VL - 35 UR - https://doi.org/10.1161/ATVBAHA.115.305688 DO - 10.1161/ATVBAHA.115.305688 ID - Miao2015 ER - TY - JOUR AU - Levenson, A. E. AU - Haas, M. E. AU - Miao, J. AU - Brown, R. J. AU - Ferranti, S. D. AU - Muniyappa, R. PY - 2016 DA - 2016// TI - Effect of leptin replacement on PCSK9 in ob/ob mice and female lipodystrophic patients JO - Endocrinology VL - 157 UR - https://doi.org/10.1210/en.2015-1624 DO - 10.1210/en.2015-1624 ID - Levenson2016 ER - TY - JOUR AU - Dong, B. AU - Singh, A. B. AU - Fung, C. AU - Kan, K. AU - Liu, J. PY - 2014 DA - 2014// TI - CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism JO - Atherosclerosis VL - 235 UR - https://doi.org/10.1016/j.atherosclerosis.2014.05.931 DO - 10.1016/j.atherosclerosis.2014.05.931 ID - Dong2014 ER - TY - JOUR AU - Zelcer, N. AU - Hong, C. AU - Boyadjian, R. AU - Tontonoz, P. PY - 2009 DA - 2009// TI - LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor JO - Science VL - 325 UR - https://doi.org/10.1126/science.1168974 DO - 10.1126/science.1168974 ID - Zelcer2009 ER - TY - JOUR AU - Rudling, M. AU - Angelin, B. PY - 1993 DA - 1993// TI - Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo JO - J Clin Investig VL - 91 UR - https://doi.org/10.1172/JCI116522 DO - 10.1172/JCI116522 ID - Rudling1993 ER - TY - JOUR AU - Drucker, D. J. AU - Nauck, M. A. PY - 2006 DA - 2006// TI - The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes JO - Lancet VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69705-5 DO - 10.1016/S0140-6736(06)69705-5 ID - Drucker2006 ER - TY - JOUR AU - Wang, Y. AU - Ye, J. AU - Li, J. AU - Chen, C. AU - Huang, J. AU - Liu, P. PY - 2016 DA - 2016// TI - Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) JO - Cardiovasc Diabetol VL - 15 UR - https://doi.org/10.1186/s12933-015-0325-x DO - 10.1186/s12933-015-0325-x ID - Wang2016 ER -